Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...
Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...
The owner of one of the three largest pharmacy middlemen in the United States filed suit on Sept. 16 to quash an attempt by ...
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices – Includes Caremark, Express Scripts, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback